Efficacy and Safety of Granulocytapheresis against severe alcoholic hepatitis
Not Applicable
Recruiting
- Conditions
- severe alcoholic hepatitis
- Registration Number
- JPRN-UMIN000019351
- Lead Sponsor
- Division of Gastroenterology & Hepatology, Department of Internal Medicine, School of Medicine, Keio University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
the patients whose granulocyte count are below 2000 the patients who complicated with severe infection, severe heart disease, uncontrolled cancer, and end-stage liver cirrhosis the patients who are pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome at 180 days after the initiation of granulocytapheresis
- Secondary Outcome Measures
Name Time Method Changes in clinical parameters including prognostic scores before and after granulocytapheresis Overall survival during observation culmative rate of discharge from Liver Unit after granulocytapheresis Culmative rate of alcoho relapse after granulocytapheresis Safty
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of granulocytapheresis in treating severe alcoholic hepatitis?
How does granulocytapheresis compare to corticosteroids in the treatment of severe alcoholic hepatitis?
What biomarkers are associated with response to granulocytapheresis in patients with severe alcoholic hepatitis?
What are the potential adverse events of granulocytapheresis and how are they managed in clinical practice?
Are there any combination therapies or alternative approaches being explored alongside granulocytapheresis for severe alcoholic hepatitis?